Paul Streck, MD, Head of R&D, commented, “As of January 23, 2025, all treatment related adverse events in CONNECT1 have been mild, and we believe that the emerging safety profile of PGN-EDO51 ...
PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...
today provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) for patients amenable to an exon-51 skipping approach. CONNECT1-EDO51 ...
BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...
Dr. Paul Streck, Head of R&D at PepGen, stated that all treatment-related adverse events in CONNECT1 have been mild and the safety profile of PGN-EDO51 appears favorable. The company remains ...
PepGen (PEPG) “provided recent updates on its CONNECT clinical program investigating PGN-EDO51 in Duchenne muscular dystrophy for patients amenable to an exon-51 skipping approach. CONNECT1 ...
H.C. Wainwright lowered the firm’s price target on PepGen (PEPG) to $16 from $26 and keeps a Buy rating on the shares after the company shared the safety reports from the CONNECT1-EDO51, the Phase 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback